Table 1. Baseline characteristics of the study population.
| Tamoxifen (n=27) | Exemestane (n=28) | |
|---|---|---|
| Age (years) | 61.15±2.74 | 61.89±4.45 |
| Tumour stage | ||
| T1 | 46% | 38% |
| T2 | 36% | 40% |
| T3 | 18% | 22% |
| Node status | ||
| N+(1–3) | 21% | 18% |
| N+(>4) | 8% | 15% |
| Negative | 71% | 67% |
| Estrogen receptor status | ||
| Positive | 100% | 100% |
| Negative | 0 | 0 |
| Progesteron receptor status | ||
| Positive | 72% | 65% |
| Negative | 28% | 35% |
| Primary treatment | ||
| Mastectomy | 61% | 54% |
| Radiotherapy | 42% | 51% |
| Chemotherapy | 24% | 27% |
| Height, cm (mean±s.d.) | 156.4±2.06 | 155.96±1.92 |
| Weight, kg (mean±s.d.) | 69.75±6.21 | 69.88±7.58 |
| BMI, kg/m2 (mean±s.d.) | 28.97±1.88 | 29.17±2.12 |
BMI=body mass index.